Switch theme
Sign up to access all valuation multiples
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
1923
2.8K+
LTM Revenue $824M
LTM EBITDA $220M
$4.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alk-Abello has a last 12-month revenue of $824M and a last 12-month EBITDA of $220M.
In the most recent fiscal year, Alk-Abello achieved revenue of $797M and an EBITDA of $201M.
Alk-Abello expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alk-Abello valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $695M | $797M | XXX | XXX | XXX |
| Gross Profit | $402M | $437M | XXX | XXX | XXX |
| Gross Margin | 58% | 55% | XXX | XXX | XXX |
| EBITDA | $131M | $201M | XXX | XXX | XXX |
| EBITDA Margin | 19% | 25% | XXX | XXX | XXX |
| Net Profit | $48.2M | $70.0M | XXX | XXX | XXX |
| Net Margin | 7% | 9% | XXX | XXX | XXX |
| Net Debt | $29.9M | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alk-Abello's stock price is DKK 145 (or $21).
Alk-Abello has current market cap of DKK 32.1B (or $4.6B), and EV of DKK 32.7B (or $4.7B).
See Alk-Abello trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.7B | $4.6B | XXX | XXX | XXX | XXX | $0.60 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alk-Abello has market cap of $4.6B and EV of $4.7B.
Alk-Abello's trades at 5.7x LTM EV/Revenue multiple, and 21.3x LTM EBITDA.
Analysts estimate Alk-Abello's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alk-Abello and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.7B | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | XXX | XXX |
| EV/EBITDA | 23.4x | XXX | XXX | XXX |
| P/E | 39.4x | XXX | XXX | XXX |
| P/E/Growth | 1.3x | XXX | XXX | XXX |
| EV/FCF | -363.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlk-Abello's NTM/LTM revenue growth is 12%
Alk-Abello's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Alk-Abello's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alk-Abello's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alk-Abello and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 53% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 37% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alk-Abello acquired XXX companies to date.
Last acquisition by Alk-Abello was XXXXXXXX, XXXXX XXXXX XXXXXX . Alk-Abello acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alk-Abello founded? | Alk-Abello was founded in 1923. |
| Where is Alk-Abello headquartered? | Alk-Abello is headquartered in Denmark. |
| How many employees does Alk-Abello have? | As of today, Alk-Abello has 2.8K+ employees. |
| Who is the CEO of Alk-Abello? | Alk-Abello's CEO is Mr. Peter Halling. |
| Is Alk-Abello publicy listed? | Yes, Alk-Abello is a public company listed on CSE. |
| What is the stock symbol of Alk-Abello? | Alk-Abello trades under ALK B ticker. |
| When did Alk-Abello go public? | Alk-Abello went public in 2005. |
| Who are competitors of Alk-Abello? | Similar companies to Alk-Abello include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Alk-Abello? | Alk-Abello's current market cap is $4.6B |
| What is the current revenue of Alk-Abello? | Alk-Abello's last 12-month revenue is $824M. |
| What is the current EBITDA of Alk-Abello? | Alk-Abello's last 12-month EBITDA is $220M. |
| What is the current EV/Revenue multiple of Alk-Abello? | Current revenue multiple of Alk-Abello is 5.7x. |
| What is the current EV/EBITDA multiple of Alk-Abello? | Current EBITDA multiple of Alk-Abello is 21.3x. |
| What is the current revenue growth of Alk-Abello? | Alk-Abello revenue growth between 2023 and 2024 was 15%. |
| Is Alk-Abello profitable? | Yes, Alk-Abello is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
